Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
accident, Addendum, aforementioned, AI, Amgen, anemia, arm, artificial, assignee, asymptomatic, BMS, Brazil, BSM, cardiovascular, carryforward, Carsten, cautionary, chair, chosen, CJEU, cloud, CODM, delegated, depiction, Deposit, desk, disaggregation, DPF, Draft, East, embodying, ERP, escalate, escalating, escalation, exhaust, faithful, FDIC, flat, foot, forensic, forfeited, Fred, grip, harbor, HARBORTM, Hutchinson, intelligence, Interagency, intragroup, Ireland, irrevocable, Jean, Kim, Lastly, leg, longevity, malware, Manual, Middle, misuse, MyoKarida, NIST, obfuscate, QMT, Quantitative, ransomware, ratably, receivership, recipient, residual, RSU, segregation, shower, steering, successor, Tamar, theft, Thompson, threat, TUG, uncollectible, underway, Unearned, Unified, Unitary, UPC, upper, vi, visiting
Removed:
analyzed, anesthesiology, approached, assumed, atrophy, bribe, broker, certified, Chairman, cleared, Codification, creatine, dealer, default, driven, essentially, exploring, fluorescence, foci, heath, hierarchical, ileum, incubation, inform, interacting, IRC, jejunum, kickback, LLP, Locana, marked, MBNL, mice, microscopy, Milo, mode, monohydrate, Murdoch, nontaxable, nuclear, Pompe, quantifiable, restatement, spread, strain, supplement, sustained, temporary, upgrading, warrant, weakened, withdrawn
Filing tables
Filing exhibits
Related press release
RNA similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-257691) and Form S-8 (Nos. 333-239148, 333-264841, and 333-268933) of Avidity Biosciences, Inc. (the "Company") of our reports dated February 28, 2024, relating to the financial statements, and the effectiveness of the Company’s internal control over financial reporting, which appear in this Annual Report on Form 10-K. Our report on the effectiveness of internal control over financial reporting expresses an adverse opinion on the effectiveness of the Company’s internal control over financial reporting as of December 31, 2023.
/s/ BDO USA, P.C.
San Diego, California
February 28, 2024